Johnson & Johnson Zytiga Study Sets Up Challenge to Dendreon

Johnson & Johnson’s prostate-cancer pill Zytiga became positioned to mount a challenge to Dendreon Corp.’s Provenge after independent monitors said J&J’s medicine was so effective it should be given to all patients in a study.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.